Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Laura Huppert, MD, BA
University of California, San Francisco
Principal Investigator - Neelima Vidula, MD
Massachusetts General Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, San Francisco
San Francisco, California, United States
- Georgetown University Hospital
Washington D.C., District of Columbia, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- Indiana University/melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
- Vanderbilt University/ingram Cancer Center
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Sept 2017
- Primary completion
- 30 Nov 2024
- Completion
- 30 Nov 2024
- Last update posted
- 22 Dec 2025
- Registered enrollment
- 76
- Registry id
- NCT03095352
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.